Stock listing

NASDAQ:RXRX Recursion Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Recursion Pharmaceuticals, Inc.

Follow Recursion Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:RXRX

$3.74 USD -0.09 (-2.5%)

Close on Oct 14, 2026

Recursion Pharmaceuticals, Inc. logo
Ticker
NASDAQ:RXRX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Recursion Pharmaceuticals (NASDAQ:RXRX) Q2 2026 Earnings Call

    Wed, Aug 05, 2026 · 8:00 AM ET

    Watch Transcript

  • Recursion Pharmaceuticals (NASDAQ:RXRX) Q1 2026 Earnings Call

    Wed, May 06, 2026 · 8:00 AM ET

    Watch Transcript

  • Recursion Pharmaceuticals (NASDAQ:RXRX) Q4 2025 Earnings Call

    Wed, Feb 25, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Oct 15, 2026

Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

Oct 15, 2026

Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone

Oct 15, 2026

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

Aug 5, 2026

Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th

Jul 29, 2026

Remix Therapeutics to Present at AACR Drug Discovery and Development Conference

Jul 16, 2026

Recursion Reports First Quarter Financial Results and Provides Business Update

May 6, 2026

Recursion Announces Board Transition

Apr 30, 2026

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

Apr 29, 2026

Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform

Mar 31, 2026

All Recursion Pharmaceuticals, Inc. news

Financings

  • Public offering of class A common stock

    Oct 15, 2026

    Announced: about US$200M · US$3.25 a share · Leerink Partners +4

    Dealers: Leerink Partners (co-lead), Goldman Sachs & Co. LLC (co-lead), Morgan Stanley & Co. LLC (co-lead), Evercore Group L.L.C. (co-lead), Needham & Company, LLC

    Buyers: Janus Henderson Investors; Invus; Longaeva Partners; ARK Invest; Driehaus Capital Management

    Use of proceeds: Advance highest-conviction programs and deliver on upcoming clinical milestones

    Announced Oct 15, 2026

Read by 6ix AI from the company's releases

Decks

Recursion Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
23 in the last 12 months · 119 in all · newest Oct 15, 2026 · oldest 2021
Calls
9 calls with a replay · 9 with a transcript · latest Aug 5, 2026
Decks
47 decks · latest Oct 15, 2026

Where Recursion Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RXRX · Home listing · This pageNASDAQUnited StatesUSD
BMV:RXRXBMVMexicoMXN
BOATS:RXRXBOATSUnited StatesUSD
gettex:A3CM1CgettexGermanyEUR
BIVA:RXRXBIVAMexicoMXN
BX Swiss:RXRXBX SwissSwitzerlandCHF
Stuttgart:8RLStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Recursion Pharmaceuticals, Inc.